Humacyte, Inc. (NASDAQ:HUMA), a company specializing in biological products, has reported that Director Brady W. Dougan has recently increased his stake in the company. According to the latest SEC filing, Dougan acquired 2,362 shares of Humacyte's common stock, with the transactions occurring on June 4, 2024.
Investors might find interest in the price range and the total value of these new acquisitions. The shares were bought at prices ranging from $6.3497 to $6.3499, averaging out to a weighted average price of $6.35 per share. The total investment made by Dougan for this batch of shares amounts to $14,998.
This purchase adds to Dougan's already substantial holdings in the company. Following this transaction, the total number of shares directly owned by Dougan's spouse is reported to be 240,832. Additionally, indirect holdings through The Niklason Living Trust and Ayabudge LLC, entities associated with Dougan, are 1,148,240 and 5,189,288 shares respectively.
The SEC filing also included a footnote indicating that the purchase by Dougan's spouse is matchable under Section 16(b) of the Securities Exchange Act of 1934 against a sale by Ayabudge LLC. The profit realized from this matched transaction has been fully paid to Humacyte, amounting to $7,015.79.
The recent transaction by a director of Humacyte is part of the regular disclosure of stock market activities by company insiders. Such filings provide transparency for investors and are a routine part of corporate governance.
InvestingPro Insights
As Humacyte, Inc. (NASDAQ:HUMA) catches the market's attention with the recent insider purchase by Director Brady W. Dougan, it's essential to consider the company's financial health and stock performance. The recent acquisition of shares by Dougan is a positive signal, but let's delve into some critical metrics from InvestingPro to get a clearer picture of the company's current standing.
One of the most striking figures is Humacyte's market capitalization, which stands at $786.55 million. This valuation reflects investor confidence in the company's potential, despite the challenges it faces. With a high Price / Book multiple of 33.56 as of the last twelve months ending Q1 2024, the company is trading at a premium compared to its book value, which could be indicative of the market's optimism about its future growth prospects.
However, it's important to note that Humacyte has been operating at a loss, with an operating income of -$101.01 million and a gross profit of -$5.7 million over the same period. Additionally, the company's P/E ratio stands at -6.66, suggesting that investors are willing to bear the current losses in anticipation of future profitability. This aligns with one of the InvestingPro Tips, which notes that analysts do not expect the company to be profitable this year.
On the performance front, Humacyte has experienced significant volatility. The stock has seen a substantial hit over the last week with a -10.95% return, yet it has also demonstrated strong returns over the last month, three months, and six months, with figures of 51.25%, 88.95%, and 155.56%, respectively. Such volatility may present both opportunities and risks for investors.
For those considering an investment in Humacyte, it may be beneficial to explore the additional 11 InvestingPro Tips available, which provide deeper insights into the company's financial status and stock performance. Interested investors can use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription at InvestingPro.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.